Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

July 31, 2001

Study Completion Date

July 31, 2001

Conditions
Parkinson's Disease
Interventions
DRUG

BIA 3-202

"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."

DRUG

Placebo

Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route

DRUG

Sinemet 25/100

Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.

Trial Locations (1)

4745-457

Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede Do Coronado

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02763839 - Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg) | Biotech Hunter | Biotech Hunter